CJC-1295 Ipamorelin

Research use only · Not FDA/EMA approved · Details

Author · the editorial desk

The editorial desk behind cjc-1295-ipamorelin.com

Every page on this site is written and kept up to date by the editorial desk of OX RESEARCH LTD.

Published 23 Sept 2026Updated 23 Sept 20263 min read

Who the desk is

It is the editorial team of OX RESEARCH LTD, a company registered in England and Wales under number 17464288. The site does not publish personal bylines, so every article carries the same signature and links here. It is not a medical team. Its pages are checked against their sources, not signed off by a clinician, and nothing on the site is medical advice. CJC-1295 and ipamorelin are investigational compounds, approved by neither the FDA nor the EMA.

What it reads

Its sources are the primary literature, not other websites. For CJC-1295 that means the ConjuChem chemistry paper of 2005 and the two trials in the Journal of Clinical Endocrinology and Metabolism in 2006. For ipamorelin it means the Novo Nordisk paper of 1998, the pharmacokinetic study of 1999 and the phase 2 trials registered by Helsinn. For the idea of pairing the two, it means the 1990 study by Bowers and colleagues. Abstracts are read on PubMed and trial records through the ClinicalTrials.gov API. Clinic pages, forums, supplier pages and encyclopedias are never cited as evidence.

How it checks a number

Before a page goes live, each DOI is requested from the CrossRef API and each trial number from the ClinicalTrials.gov API. A reference that does not answer with HTTP 200 is dropped. Today the site cites 24 sources, 19 with a DOI and 5 with a registry number. Figures are quoted in the units the authors used, with the population and the duration they apply to. Doses appear only as the doses of the studies cited and are never recommended. The desk publishes no protocols, no testimonials and no reviews. All nine rules are set out in the editorial policy.

Who pays for it, and the link to OXpeptides

OX RESEARCH LTD publishes this site and also runs OXpeptides, a supplier of research peptides. The product link on each page goes to the CJC-1295 / ipamorelin blend at oxpeptides.com, sold by that same company. This is a conflict of interest, and the site states it on every page instead of hiding it. The vendor comparison on the main article quotes what each vendor's own pages showed on the date given, next to the scoring grid, so a reader can score the vendors again without trusting the desk. The site carries no advertising and no analytics.

Articles signed by the desk

The desk also keeps 9 shorter guides that are not listed in search engines for now, so they are not linked from this page.

Contact and corrections

Write to editor@cjc-1295-ipamorelin.com. A correction is made on the page where the error sits, the updated date changes, and a note goes at the foot of the page when a figure changes. A message that cites a DOI or an NCT number is answered first. More on the method is on the about page.

Informational content, not medical advice. CJC-1295 and ipamorelin are investigational research compounds, not approved by the FDA or the EMA for any use.